Skip to main content
    V

    Vivos Therapeutics Inc (VVOS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.08
    -0.02 (-16.12%)

    Market Cap: $3.29M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vivos Therapeutics Inc (VVOS) Earnings: Report Dates and Results

    Updated Aug 14, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Vivos Therapeutics (VVOS) is expected to report earnings on Nov 17, 2026. In the quarter ended Jun 30, 2026, Vivos Therapeutics reported EPS of -$0.31, above the -$0.42 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    30%(7/23)
    Avg Surprise
    -21.16%
    Streak
    1 Q

    Upcoming Estimates

    Reports Nov 17, 2026 (est.)Period ending Sep 30, 2026
    EPS Consensus-$0.32
    Range-$0.54 - -$0.12
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.30-5.8%
    60d ago-$0.30-5.8%
    30d ago-$0.30-5.8%
    7d ago-$0.30-5.8%
    Current-$0.32
    Revenue Consensus
    $5.47M
    Range$5.47M - $5.47M
    1 analysts
    Reports Apr 13, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.27
    Range-$0.51 - -$0.07
    6 analysts
    Revenue Consensus
    $6.76M
    Range$5.88M - $8.24M
    6 analysts

    Next Report

    VVOS has an expected report date of Nov 17, 2026.

    VVOS Earnings Call

    The latest VVOS earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, VVOS beat 7 and missed 16. Revenue for the quarter ended Jun 30, 2026 was $5.15M, up 34.8% from $3.82M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.31-$0.42-$0.54 - -$0.29+26.19%BeatN/A40 up, 0 downAug 14, 2026$5.15M
    Mar 31, 2026-$0.52-$0.45-$0.49 - -$0.40-15.56%MissN/A30 up, 0 downApr 15, 2026$5.14M
    Dec 31, 2025-$0.58-$0.50-$0.53 - -$0.46-17.17%MissN/A30 up, 0 downMar 26, 2026$3.82M
    Sep 30, 2025-$0.49-$0.51-$0.55 - -$0.48+3.92%BeatN/A30 up, 1 downNov 19, 2025$6.78M
    Jun 30, 2025-$0.55-$0.38-$0.38 - -$0.38-44.74%MissN/A10 up, 1 downAug 19, 2025$3.82M
    Mar 31, 2025-$0.45-$0.44-$0.44 - -$0.36-2.27%MissN/A20 up, 1 downMay 15, 2025$3.02M
    Dec 31, 2024-$0.28-$0.43-$0.43 - -$0.43+34.88%BeatN/A11 up, 0 downMar 31, 2025$3.70M
    Sep 30, 2024-$0.40-$0.70-$0.70 - -$0.70+42.86%BeatN/A11 up, 0 downNov 14, 2024$3.86M
    Jun 30, 2024-$0.60-$1.05-$1.05 - -$1.05+42.86%BeatN/A10 up, 0 downAug 14, 2024$4.05M
    Mar 31, 2024-$1.63-$1.16-$1.19 - -$1.16-40.52%Miss-209.4%20 up, 0 downMay 14, 2024$3.42M
    Dec 31, 2023-$3.05-$1.90-$2.06 - -$1.75-60.53%MissN/A20 up, 0 downMar 28, 2024$3.25M
    Sep 30, 2023-$3.08-$3.00-$3.25 - -$3.00-2.67%MissN/A20 up, 0 downNov 14, 2023$3.30M
    Jun 30, 2023-$3.89-$3.50-$3.75 - -$3.50-11.14%MissN/A20 up, 0 downAug 16, 2023$3.40M
    Mar 31, 2023$1.49-$4.75-$4.75 - -$4.25+131.37%BeatN/A20 up, 0 downJun 8, 2023$3.86M
    Dec 31, 2022-$0.20-$0.22-$0.22 - -$0.22+9.09%BeatN/A20 up, 0 downMar 30, 2023$3.95M
    Sep 30, 2022-$6.50-$6.25N/A-4.00%MissN/AN/A0 up, 0 downDec 20, 2022$4.25M
    Jun 30, 2022-$0.28-$0.25N/A-12.00%MissN/AN/A0 up, 0 downAug 23, 2022$4.18M
    Mar 31, 2022-$8.01-$6.50-$7.25 - -$5.75-23.23%MissN/A20 up, 0 downMay 16, 2022$3.64M
    Dec 31, 2021-$0.34-$0.25-$0.27 - -$0.23-36.00%MissN/A2N/AMar 31, 2022$4.39M
    Sep 30, 2021-$6.50-$4.62-$5.25 - -$4.00-40.69%MissN/A2N/ANov 15, 2021$4.55M
    Jun 30, 2021-$4.75-$4.50-$5.00 - -$4.00-5.56%MissN/A2N/AAug 12, 2021$4.50M
    Mar 31, 2021-$4.75-$4.25-$4.25 - -$4.25-11.76%MissN/A2N/AMay 17, 2021$3.45M
    Dec 31, 2020-$0.88-$0.16-$0.21 - -$0.12-450.00%MissN/A2N/AMar 25, 2021$16.37M
    Sep 30, 2020-$0.23N/AN/AN/AN/AN/AN/AN/ADec 14, 2020$3.29M
    Jun 30, 2020-$0.16N/AN/AN/AN/AN/AN/AN/ASep 30, 2020$3.27M
    Mar 31, 2020-$0.18N/AN/AN/AN/AN/AN/AN/AJun 29, 2020$3.20M
    Dec 31, 2019-$0.18N/AN/AN/AN/AN/AN/AN/AMar 31, 2020$3.06M
    Jun 30, 2019-$0.27N/AN/AN/AN/AN/AN/AN/ASep 30, 2019$2.51M
    Mar 31, 2019-$0.23N/AN/AN/AN/AN/AN/AN/AJun 29, 2019$2.51M
    Dec 31, 2018-$0.23N/AN/AN/AN/AN/AN/AN/AMar 30, 2019N/A
    Last 30 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.07, after -$2.91 the year before. It was -$0.23 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.07N/A
    Dec 31, 2024-$2.91N/A
    Dec 31, 2023-$8.53N/A
    Dec 31, 2022-$14.99N/A
    Dec 31, 2021-$16.34N/A
    Dec 31, 2020-$1.45N/A
    Dec 31, 2019-$0.67N/A
    Dec 31, 2018-$0.23N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,900 words across 4 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20264,9044
    2026Q1Mar 31, 20264,0354
    2025Q4Dec 31, 20256,7025
    2025Q3Sep 30, 20255,0305
    2025Q2Jun 30, 20255,0685
    2025Q1Mar 31, 20254,7665
    2024Q3Sep 30, 20247,5026
    2024Q2Jun 30, 20244,9546

    2026Q2 Earnings Call

    Opening remarks

    Bradford K. Amman Principal Accounting Officer and former CFO Thank you, Ludy. Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com. With me on the call today is Kirk Huntsman, Vivos' Chairman and Chief Executive Officer; and Roman Franklin, Vivos' Chief Financial Officer and Principal Financial Officer. Today, we will review the financial results of the second quarter of 2026 as well as more recent developments and Vivos' plans for the rest of the year 2026 and beyond. Following these formal remarks, we will be happy to take questions. I would also like to remind everyone that today's call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities and Exchange Act of 1934 as amended, concerning future events. Words such as aim, may, could, should, projects, expects, intends, plans, believes, anticipates, hopes, estimates, goal and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant risks, uncertainties and contingencies, many of which are beyond the company's control. Actual results, including, without limitation, the results of Vivos' growth strategies, operational plans, including sales, marketing, distribution, medical sleep provider, acquisition and integration, research and development, regulatory initiatives, cost savings plans and plans to generate revenue as well as future potential results of operations or operating metrics such as the potential for Vivos to achieve future positive cash flows or profitability and other matters to be addressed by Vivos' management in this conference call may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in other disclosures contained in Vivos' filings with the Securities and Exchange Commission, including the risk factors and other disclosures in our Form 10-K for the year ended December 31, 2025, and our other filings with the SEC including our second quarter 10-Q filed with the SEC today, all of which are, or will be accessible on the Investor Relations section of the Vivos website as well as the SEC's website. Except to the extent required by law, Vivos assumes no obligation to update statements as circumstances change. Finally, please be aware that the U.S. Food and Drug Administration has given certain specific Vivos appliances 510(k) clearance to treat mild to severe OSA in adults.

    Frequently Asked Questions About VVOS

    When is Vivos Therapeutics's next earnings date?

    Vivos Therapeutics's next earnings report is expected for Nov 17, 2026.

    Did VVOS beat earnings estimates last quarter?

    Yes. Vivos Therapeutics reported EPS of -$0.31 for the quarter ended Jun 30, 2026, above the -$0.42 estimate, a 26.19% surprise.

    What EPS do analysts expect from VVOS next quarter?

    The consensus EPS estimate for Vivos Therapeutics for the quarter ended Sep 30, 2026 is -$0.32 from 3 analysts, with estimates from -$0.54 to -$0.12.

    How often does VVOS beat earnings estimates?

    Vivos Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +3.51%.